or Try an Advanced Search...

    Cancer Treatment Stocks List

    Symbol Grade Name % Change
    REPL D Replimune Group, Inc. -1.60
    SLS D SELLAS Life Sciences Group, Inc. -1.61
    PSTX D Poseida Therapeutics, Inc. -0.37
    CASI D CASI Pharmaceuticals, Inc. -0.19
    MRKR D Marker Therapeutics, Inc. -7.18
    OTLK D Outlook Therapeutics, Inc. -2.84
    PYXS D Pyxis Oncology, Inc. -45.03
    IPHA D Innate Pharma S.A. 0.86
    CLDX F Celldex Therapeutics, Inc. -0.68
    RCUS F Arcus Biosciences, Inc. -2.33
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Insurance - Diversified Medical Instruments & Supplies
    Related Stock Lists: Cancer Medicine Clinical Medicine Antineoplastic Drugs Biotechnology Biopharmaceutical Immune System Immunotherapy Solid Tumors Advanced Solid Tumors Cancer Cell Cancer Immunotherapy Cancer Immunotherapy Product Checkpoint Inhibitor Chemotherapy Drugs Epidermal Growth Factor Receptor Immunotherapy Products Lymphoma Milatuzumab

    Related ETFs - A few ETFs which own one or more of the above listed Cancer Treatment stocks.

    Symbol Grade Name Weight
    FTXH D First Trust Nasdaq Pharmaceuticals ETF 8.89
    MEDX F Horizon Kinetics Medical ETF 6.23
    PPH D Market Vectors Pharmaceutical ETF 5.89
    MVAL B SHL Telemedicine Ltd VanEck Morningstar Wide Moat Value ETF 5.37
    RDIV A RevenueShares Ultra Dividend Fund 5.27
    View all Cancer Treatment ETFs...
    Compare ETFs
    Compare MEDX to PPH Compare MVAL to RDIV Compare PPH to RDIV

        Cancer Treatment Stocks Recent News

        Date Stock Title
        Nov 21 PYXS Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
        Nov 21 PYXS Pyxis stock craters 46% amid Phase 1 data, William Blair downgrade
        Nov 20 PYXS Pyxis Oncology plummets 38% on preliminary phase 1 data for cancer asset
        Nov 20 PYXS Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data
        Nov 20 CLDX Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
        Nov 20 CLDX Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
        Nov 19 RCUS Arcus Biosciences to Participate in Two Upcoming Investor Conferences
        Nov 17 MRKR Marker Therapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 17 CASI CASI Pharmaceuticals Third Quarter 2024 Earnings: Beats Expectations
        Nov 16 SLS We're A Little Worried About SELLAS Life Sciences Group's (NASDAQ:SLS) Cash Burn Rate
        Nov 15 CASI CASI Pharmaceuticals reports Q3 results
        Nov 15 CASI CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results
        Related Industries: Biotechnology Diagnostics & Research Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic Insurance - Diversified Medical Instruments & Supplies
        Related Stock Lists: Cancer Biopharmaceutical Clinical Medicine Antineoplastic Drugs Medicine Solid Tumors Melanoma Advanced Non Small Cell Lung Cancer Biotechnology Cancer Immunotherapy Cancer Therapies Epidermal Growth Factor Receptor Multiple Myeloma NSCLC Non Small Cell Lung Cancer Organic Chemistry Orphan Drug Protein Kinase Small Cell Lung Cancer Acid
        Cancer Treatment

        Cancer treatment is the use of medical therapies to treat cancer. These treatments may include surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapy. The goal of cancer treatment is to remove or destroy the cancer cells, reduce symptoms, and improve quality of life.

        Browse All Tags